Vascular factors in Parkinson’s disease with cognitive impairment
Objective: To review the relationship between vascular related factors and cognitive impairment in Parkinson's disease. Background: Parkinson's disease is a chronic, progressive, neurodegenerative disease that…Maladaptive motor cortex plasticity off medication in Parkinson’s disease patients with levodopa-induced dyskinesias
Objective: To test the hypothesis that motor cortex plasticity is maladaptive in Parkinson's disease (PD) patients suffering from dyskinesias, as compared to non-dyskinetic patients. Background:…An agent-based model replicates the pathogenic spread of alpha-synuclein in mice
Objective: To investigate the ability of a susceptible-infected-removed (SIR) agent-based model to predict the pathogenic spread of alpha-synuclein fibrils after injection in mice. Background: Parkinson’s…Improving Diagnosis and Treatment of Anxiety in Parkinson’s Disease: IDATA-PD Study Update
Objective: 1. To develop an inventory to assess Parkinson’s disease (PD) specific anxiety for person centred psychotherapy interventions. 2. To develop manualised cognitive behaviour therapy…Risk of Suicidal Ideation After Deep Brain Stimulation Surgery in Patients with Parkinson’s Disease
Objective: To explore the association of preoperative risk factors with postoperative suicidal ideation in patients with Parkinson’s disease (PD) who had deep brain stimulation (DBS)…Phase I-II first-in-human clinical trial of intraputamenal CDNF in Parkinson’s disease: Topline results of the six-month double-blind placebo-controlled main study and the six-month active treatment extension study
Objective: To assess the safety and tolerability and to explore the preliminary efficacy of intermittent intraputamenal monthly infusions of CDNF in subjects with advanced idiopathic…The Levodopa in Early Parkinson’s disease (LEAP) study: Post-hoc analyses
Objective: We present the results of several post hoc analyses of the LEAP-study. Background: Among patients with Parkinson’s disease who were evaluated in the LEAP-study…Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson’s Disease Patients with and without LRRK2 mutations
Objective: To evaluate safety, tolerability, and target engagement of DNL201, a LRRK2 inhibitor, in Parkinson’s disease (PD) patients. Background: Mutations in LRRK2 impact both familial…Cardiovascular Fitness, Plasma Biomarkers and Dopaminergic Denervation in Parkinson’s Disease
Objective: To examine the relationship between cardiovascular (CV) fitness, plasma biomarkers associated with PD progression and/or exercise and dopaminergic denervation, measured by I-123-Ioflupane single photon…A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment (TEAL Study)
Objective: Assessment of efficacy and safety in subjects with Parkinson’s disease (PD) following treatment for 12 weeks with placebo or AKST4290, a highly specific and…
- « Previous Page
- 1
- …
- 57
- 58
- 59
- 60
- 61
- …
- 149
- Next Page »